CD8A and breast carcinoma: Specifically, the authors assessed the status of PD-L1, PD-1, CTLA-4, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, and Ki67 along with pan Cytokeratin and CD31 in the TME of 3098 tumors, including 587 cases with breast cancer.